OGN News and Press, Organon & Co.

Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 Organon (NYSE: OGN), a global healthcare company wi...

2026-02-24 06:03:50 ET from Barclays issued a price target of $8.00 for OGN on 2026-02-24 10:45:11. The adjusted price target was set to $8.00. At the time of the announcement, OGN was trading at $7.92. The overall price target consensus is at $6.25 with high price of $7...

MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every d...

2026-02-22 04:56:59 ET Investment thesis Read the full article on Seeking Alpha For further details see: Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty

2026-02-20 08:20:06 ET More on Organon Organon & Co. 2025 Q4 - Results - Earnings Call Presentation Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off Organon & Co. (OGN) Q4 2025 Earnings Call Transcript Organon outlines flat $6.2B ...

2026-02-18 10:00:00 ET Read the full article on Seeking Alpha For further details see: IXJ: Healthcare Sector Dashboard For February

2026-02-12 12:43:18 ET Investment Overview Organon ( OGN ), the New Jersey-headquartered global healthcare company, reported its Q4 and full-year 2025 earnings earlier today, and somewhat predictably, results appear to have disappointed the market. The stock is down >10% at t...

2026-02-12 12:33:55 ET Image source: The Motley Fool. Feb. 12, 2026 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-12 10:45:34 ET More on Organon Organon & Co. (OGN) Q4 2025 Earnings Call Transcript Organon: Deep Value With No Clear Catalysts Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript Organon falls as women&#...

2026-02-12 10:44:42 ET Organon & Co. (OGN) Q4 2025 Earnings Call February 12, 2026 8:30 AM EST Company Participants Jennifer Halchak - Head of Investor Relations Joseph Morrissey - Interim CEO & Executive VP and Head of Manufacturing & Supply Matthew Wa...